Summary

The global pharmaceutical drug delivery market is projected to reach USD 2,546.0 billion by 2029 from USD 1,949.4 billion in 2024 at a CAGR of 5.5% during the forecast period. The rapid growth in the geriatric population globally and the significant rise in the patients with chronic diseases are expected to boost the demand for pharmaceutical drug delivery market. Moreover, gradual rise in utilization of home care and self administration is likely to support the market growth. Advancements in drug delivery technology, new product launches, robust pharmaceutical R&D investments by key companies and government policies, investments in healthcare infrastructure, and initiatives to enhance the accessibility and affordability of drug delivery products is anticipated to fuel the market growth.

“The injectable drug delivery segment of pharmaceutical drug delivery market to grow with the highest CAGR during the forecast period.”
Based on the pharmaceutical drug delivery market, the injectable drug delivery segment is anticipated to grow at significant rate during forecast period. Due to increasing prevalence of chronic disease. Injectables are used in many therapeutic areas, such as hormonal disorders, oncology, autoimmune diseases, and orphan diseases. The injectable route is a promising alternative over oral drug delivery.Moreover it also maximize patient compliance, and reduce the frequency of dosage administration .Also, Due to increased preference in self-administration and home care, there has been significant development and advancement in injectables that have helped in minimizing the exposure of needles as well as the pain associated with them.These factors are fostering the growth of injectable drug delivery at higher pace.



“The Cancer segment to capture the largest market share of pharmaceutical drug delivery market.”
Based on application the Pharmaceutical drug delivery market are segmented into infectitous diseases, cancer, autoimmune disease, diabetes other disease indications The cancer segment held the largest market share during the forecast period. Cancer forms a key therapeutic application segment for drug delivery technologies. Pharmaceutical drug delivery technologies are widely used in various therapies, such as chemotherapy, hormone therapy, target therapy, and immunotherapy. The incidence of cancer has surged rapidly across the globe. According to the WHO, in 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths. Owing to this, companies are increasingly focusing on developing novel medicines for cancer; this is expected to drive the growth of this therapeutic segment.


“North America accounted for the largest share of the pharmaceutical drug delivery market by region.”
The global pharmaceutical drug delivery market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the largest regional market for pharmaceutical drug delivery products and services , whereas the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period.
The largest share of North America can be attributed to the high disease burden of chronic disease contributing to a larger pool of patients requiring pharmaceutical drug delivery products. The presence of numerous potentialphaemaceutical giants ,surge in medical procedures , and favorable reimbursement policy in the region is likely to promote the growth of pharmaceutical drug delivery market in North America.


A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–35%, Tier 2–45%, and Tier 3– 20%
• By Designation: C-level–35%, Director-level–25%, and Others–40%
• By Region: North America–45%, Europe–30%, Asia Pacific–20%, Latin America–3%, and the Middle East & Africa–2%

The major players operating in the pharmaceutical drug delivery market market are Johnson & Johnson services, inc (US), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (US),,), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), Sanofi (France), Bayer AG (Germany), Amgen, Inc. (US).

Research Coverage

This report studies the pharmaceutical drug delivery market based on pharmaceutical drug delivery, route of administration, application, facility of use and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:
 Analysis of Key divers (increasing prevalence of chronic disease, technological advancement in pharmaceutical drug delivery technologies, new product launches, growing investments in pharmaceutical R&D), restraints (high cost of development, risk of needlestick injuries) , Opportunities (emerging markets, gradual shift towards homecare and self administration) , Challenge (pricing pressure)
 Market Penetration: Comprehensive information on the product portfolios offered by the top players in the pharmaceutical drug delivery market
 Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the pharmaceutical drug delivery market
 Market Development: Comprehensive information on lucrative emerging regions
 Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the pharmaceutical drug delivery market
 Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 56
1.1 STUDY OBJECTIVES 56
1.2 MARKET DEFINITION 56
1.2.1 INCLUSIONS & EXCLUSIONS 57
1.3 STUDY SCOPE 57
1.3.1 MARKETS COVERED 57
1.3.2 YEARS CONSIDERED 58
1.3.3 CURRENCY CONSIDERED 58
1.4 MAJOR STAKEHOLDERS 59
1.5 SUMMARY OF CHANGES 59
2 RESEARCH METHODOLOGY 60
2.1 RESEARCH APPROACH 60
2.1.1 SECONDARY RESEARCH 61
2.1.1.1 Key data from secondary sources 62
2.1.2 PRIMARY RESEARCH 62
2.1.2.1 Insights from primary experts 64
2.1.2.2 Breakdown of primaries 64
2.2 MARKET SIZE ESTIMATION 65
2.3 MARKET SHARE ESTIMATION 70
2.4 STUDY ASSUMPTIONS 71
3 EXECUTIVE SUMMARY 72
4 PREMIUM INSIGHTS 76
4.1 PHARMACEUTICAL DRUG DELIVERY MARKET OVERVIEW 76
4.2 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE AND COUNTRY 77
4.3 PHARMACEUTICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 78
5 MARKET OVERVIEW 79
5.1 MARKET DYNAMICS 79
5.1.1 DRIVERS 80
5.1.1.1 Rising prevalence of chronic diseases 80
5.1.1.2 Technological advancements and product launches 80
5.1.1.3 Rising investments in pharmaceutical R&D 81
5.1.1.4 Growing emphasis on patient convenience 82
5.1.1.5 Government initiatives to boost affordability 83
 
5.1.2 RESTRAINTS 83
5.1.2.1 High development costs 83
5.1.3 OPPORTUNITIES 84
5.1.3.1 Increased preference for self-administration and home care 84
5.1.3.2 Rising interest in biosimilars and biologics 84
5.1.3.3 Market opportunities in emerging economies 86
5.1.3.4 Development of biocompatible materials for drug delivery systems 87
5.1.4 CHALLENGES 87
5.1.4.1 Pricing pressure from governing bodies 87
5.1.4.2 Risk of needlestick injuries 88
5.2 REGULATORY LANDSCAPE 88
5.2.1 NORTH AMERICA 89
5.2.1.1 US 89
5.2.1.2 Canada 89
5.2.2 EUROPE 89
5.2.2.1 Germany 89
5.2.2.2 Italy 89
5.2.2.3 France 89
5.2.2.4 UK 90
5.2.2.5 Switzerland 90
5.2.3 ASIA PACIFIC 90
5.2.3.1 China 90
5.2.3.2 Japan 90
5.2.3.3 India 90
5.2.3.4 South Korea 91
5.2.3.5 Australia 91
5.2.4 LATIN AMERICA 91
5.2.5 MIDDLE EAST & AFRICA 91
5.2.6 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
5.3 VALUE CHAIN ANALYSIS 95
5.4 SUPPLY CHAIN ANALYSIS 96
5.4.1 PROMINENT COMPANIES 96
5.4.2 SMALL & MEDIUM-SIZED COMPANIES 96
5.4.3 END USERS 96
5.5 ECOSYSTEM ANALYSIS 97
5.6 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 98
5.7 TECHNOLOGY ANALYSIS 98
5.7.1 KEY TECHNOLOGIES 98
5.7.2 AUTOMATED INSULIN DELIVERY (AID) 98
5.7.2.1 Wearable patches 99
5.7.2.2 On-body drug delivery systems 99
5.7.2.3 Needle-free drug delivery systems 99
5.7.2.4 3D printing 100
5.7.2.5 Responsive hydrogels 100
5.7.2.6 Exosomes and extracellular vesicles 100
5.7.2.7 Polymeric particles and implants 100
5.7.2.8 Atomic layer deposition 100
5.7.2.9 Ingestible injectables 100
5.7.2.10 Ocular drug delivery 101
5.7.3 COMPLEMENTARY TECHNOLOGIES 101
5.7.3.1 Pen injectors 101
5.7.3.2 Prefilled syringes 101
5.7.3.3 Autoinjector technology 101
5.7.3.4 Nanotechnology 101
5.8 TRADE ANALYSIS 102
5.8.1 TRADE ANALYSIS FOR SYRINGES, WITH OR WITHOUT NEEDLES, USED IN MEDICAL, SURGICAL, DENTAL, OR VETERINARY SCIENCES 102
5.8.2 TRADE ANALYSIS FOR MEDICAMENTS IN MEASURED DOSES, INCLUDING TRANSDERMAL ADMINISTRATION 104
5.9 PATENT ANALYSIS 105
5.9.1 PATENT PUBLICATION TRENDS FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES 105
5.9.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 106
5.10 PORTER’S FIVE FORCES ANALYSIS 110
5.10.1 THREAT OF NEW ENTRANTS 111
5.10.2 THREAT OF SUBSTITUTES 111
5.10.3 BARGAINING POWER OF SUPPLIERS 111
5.10.4 BARGAINING POWER OF BUYERS 111
5.10.5 INTENSITY OF COMPETITIVE RIVALRY 112
5.11 KEY STAKEHOLDERS & BUYING CRITERIA 112
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 112
5.11.2 BUYING CRITERIA 113
5.12 PRICING ANALYSIS 114
5.13 KEY CONFERENCES & EVENTS (2024–2025) 116
5.14 REIMBURSEMENT ANALYSIS 117
5.15 CASE STUDY ANALYSIS 119
5.16 INVESTMENT & FUNDING SCENARIO 120
5.17 UNMET NEEDS IN PHARMACEUTICAL DRUG DELIVERY MARKET 120
5.18 END-USER EXPECTATIONS IN PHARMACEUTICAL DRUG DELIVERY MARKET 121
5.19 AI INTEGRATION IN PHARMACEUTICAL DRUG DELIVERY MARKET 121
 
6 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION 123
6.1 INTRODUCTION 124
6.2 INJECTABLE DRUG DELIVERY 124
6.2.1 CONVENTIONAL INJECTION DEVICES 126
6.2.1.1 Conventional injection devices market, by material 128
6.2.1.1.1 Glass syringes 128
6.2.1.1.1.1 Durability and safety to drive adoption 128
6.2.1.1.2 Plastic syringes 130
6.2.1.1.2.1 Lower price compared to glass syringes to propel adoption 130
6.2.1.2 Conventional injection devices market, by product 132
6.2.1.2.1 Fillable syringes 132
6.2.1.2.1.1 Ease of use and variable dosing formulations of fillable syringes to drive market 132
6.2.1.2.2 Prefilled syringes 134
6.2.1.2.2.1 Improved dose accuracy and increased patient convenience & safety to support usage 134
6.2.1.3 Conventional injection devices market, by usability 136
6.2.1.3.1 Reusable syringes 136
6.2.1.3.1.1 Ease of use, dismantling, and cleaning to support market growth 136
6.2.1.3.2 Disposable syringes 138
6.2.1.3.2.1 Low cost and convenience to favor end-user demand 138
6.2.2 SELF-INJECTION DEVICES 140
6.2.2.1 Needle-free injectors 142
6.2.2.1.1 Rapid drug delivery and better reproducibility than invasive drug delivery systems to support market growth 142
6.2.2.2 Autoinjectors 143
6.2.2.2.1 Improved patient satisfaction compared to manual injections to drive market 143
6.2.2.3 Pen injectors 145
6.2.2.3.1 Need for multi-dose devices to propel adoption 145
6.2.2.4 Wearable injectors 147
6.2.2.4.1 Increasing adoption of home infusion therapy and rising focus on cost-curtailment in healthcare to support market growth 147
6.3 ORAL DRUG DELIVERY 149
6.3.1 SOLID ORAL DRUGS 151
6.3.1.1 Tablets 153
6.3.1.1.1 Development of mini-tablets to propel market growth 153
6.3.1.2 Capsules 155
6.3.1.2.1 Easy absorption of drugs and decreased irritation in GI tract drive capsule usage 155
6.3.1.3 Oral powders 157
6.3.1.3.1 Convenience for patients with trouble swallowing other dosage forms to propel usage 157
6.3.1.4 Pills 159
6.3.1.4.1 Rising incidence of target ailments to propel market growth 159
6.3.2 LIQUID ORAL DRUGS 161
6.3.2.1 Oral syrups 162
6.3.2.1.1 Ease of administration to drive usage 162
6.3.2.2 Oral solutions 164
6.3.2.2.1 Rising preference among geriatric and pediatric patients to support adoption 164
6.3.2.3 Oral emulsions 165
6.3.2.3.1 Enhanced solubility, stability, and ease of administration to drive market 165
6.3.2.4 Oral elixirs 167
6.3.2.4.1 Rising preference in pediatric cases to drive market 167
6.3.3 SEMI-SOLID ORAL DRUGS 169
6.3.3.1 Oral gels 171
6.3.3.1.1 Controlled drug release benefits to propel usage 171
6.3.3.2 Oral pastes 173
6.3.3.2.1 Protection against oxidation and enzymatic hydrolysis to support adoption 173
6.4 TOPICAL DRUG DELIVERY 175
6.4.1 SEMI-SOLID TOPICAL FORMULATIONS 177
6.4.1.1 Topical creams 179
6.4.1.1.1 Variable efficacy to affect end-user adoption 179
6.4.1.2 Topical gels 180
6.4.1.2.1 Faster drug release and greater patient acceptability to drive the market for topical gels 180
6.4.1.3 Topical ointments 181
6.4.1.3.1 Wide usage in analgesic indications to drive market 181
6.4.1.4 Topical pastes 182
6.4.1.4.1 Wide usage in treating/preventing skin irritation to support growth 182
6.4.1.5 Topical lotions 183
6.4.1.5.1 Ease of administration of lotions to drive demand 183
6.4.2 LIQUID TOPICAL FORMULATIONS 184
6.4.2.1 Topical suspensions 186
6.4.2.1.1 High bioavailability and controlled onset of action to support adoption 186
6.4.2.2 Topical emulsions 188
6.4.2.2.1 Improved spreadability, stability, and controlled release of active ingredients 188
6.4.2.3 Topical solutions 190
6.4.2.3.1 Ease of use and ready availability to support market growth 190
6.4.3 SOLID TOPICAL FORMULATIONS 191
6.4.3.1 Topical powders 193
6.4.3.1.1 Rising incidence of skin disorders to drive market 193
6.4.3.2 Suppositories 195
6.4.3.2.1 Compatibility and stability to support growth 195
6.4.4 TRANSDERMAL PRODUCTS 196
6.4.4.1 Transdermal patches 198
6.4.4.1.1 Prevention of premature metabolization of drugs to drive market 198
6.4.4.2 Transdermal gels 200
6.4.4.2.1 Rapid drug release capabilities to support usage of gels 200
6.4.4.3 Transdermal sprays 201
6.4.4.3.1 Simplicity and noninvasive nature to support adoption 201
6.5 OCULAR DRUG DELIVERY 203
6.5.1 LIQUID OCULAR FORMULATIONS 204
6.5.1.1 Eye drops 206
6.5.1.1.1 Rising prevalence of cataracts and other eye diseases to drive market growth 206
6.5.1.2 Liquid ocular sprays 208
6.5.1.2.1 Benefits over eye drops to support market growth 208
6.5.2 SEMI-SOLID OCULAR FORMULATIONS 209
6.5.2.1 Ocular gels 211
6.5.2.1.1 High viscosity, prolonged drug release, and ease of drug administration to support market growth 211
6.5.2.2 Eye ointments 212
6.5.2.2.1 Safety and efficient administration to drive market 212
6.5.3 OCULAR DEVICES 214
6.5.3.1 Ocular inserts 216
6.5.3.1.1 Support for sustained drug release to drive adoption 216
6.5.3.2 Drug-coated contact lenses 217
6.5.3.2.1 Better eyesight offered by lenses and high compliance to drive market 217
6.6 PULMONARY DRUG DELIVERY 219
6.6.1 METERED-DOSE INHALERS 221
6.6.1.1 Support for coordinating inhaler actuation and patient breath to drive adoption 221
6.6.2 DRY POWDER INHALERS 223
6.6.2.1 Chemical stability of formulations to support usage 223
6.6.3 NEBULIZERS 225
6.6.3.1 Jet nebulizers 227
6.6.3.1.1 Jet nebulizers to account for largest share of nebulizers market 227
6.6.3.2 Ultrasonic nebulizers 228
6.6.3.2.1 Ease of use and comfort for patients to propel adoption 228
6.6.3.3 Soft mist nebulizers 230
6.6.3.3.1 Rising preference in COPD treatment to propel market 230
6.7 NASAL DRUG DELIVERY 232
6.7.1 NASAL SPRAYS 233
6.7.1.1 Applications in relieving nasal congestion, runny nose, itchy nose, and sneezing to support adoption 233
6.7.2 NASAL DROPS 235
6.7.2.1 Efficiency over nasal sprays to drive adoption 235
6.7.3 NASAL GELS 236
6.7.3.1 Long-lasting relief and reduced irritation to support growth 236
6.7.4 NASAL POWDERS 238
6.7.4.1 Absence of preservatives and stability of formulations to support adoption 238
6.8 TRANSMUCOSAL DRUG DELIVERY 239
6.8.1 ORAL TRANSMUCOSAL FORMULATIONS 242
6.8.2 BUCCAL DRUG DELIVERY 244
6.8.2.1 Applications in local and systematic therapies to drive adoption 244
6.8.2.2 Sublingual drug delivery 246
6.8.2.2.1 High rate of adoption to propel usage 246
6.8.3 OTHER TRANSMUCOSAL FORMULATIONS 248
6.8.3.1 Rectal drug delivery 250
6.8.3.1.1 High vascularization to support rapid drug absorption 250
6.8.3.2 Vaginal drug delivery 252
6.8.3.2.1 Higher permeability and drug stability to drive market 252
6.9 IMPLANTABLE DRUG DELIVERY 254
6.9.1 PASSIVE IMPLANTABLE DRUG DELIVERY 256
6.9.1.1 Targeted drug delivery benefits to propel market 256
6.9.2 ACTIVE IMPLANTABLE DRUG DELIVERY 258
6.9.2.1 Need for better diagnostic monitoring and body fluid transportation to favor market growth 258
7 PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION 260
7.1 INTRODUCTION 261
7.2 INFECTIOUS DISEASES 262
7.2.1 HIGH BURDEN OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH 262
7.3 CANCER 264
7.3.1 GROWING INCIDENCE OF CANCER TO ENSURE DEMAND FOR THERAPY 264
7.4 CVD 266
7.4.1 INCREASING PREVALENCE AND INCREASING INNOVATION IN DRUG DELIVERY TECHNOLOGIES TO PROPEL MARKET GROWTH 266
7.5 DIABETES 268
7.5.1 EMERGENCE OF NEW TECHNOLOGIES TO SUPPORT MARKET GROWTH 268
 
7.6 RESPIRATORY DISEASES 270
7.6.1 HIGH PREVALENCE OF ASTHMA AND COPD TO DRIVE ADOPTION OF PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES 270
7.7 CNS DISORDERS 272
7.7.1 WIDE USAGE OF ORAL AND INJECTABLE DRUG DELIVERY SYSTEMS TO DRIVE MARKET 272
7.8 AUTOIMMUNE DISEASES 274
7.8.1 AUTOIMMUNE DISEASES TO REGISTER HIGHEST GROWTH 274
7.9 OTHER APPLICATIONS 276
7.9.1 OPHTHALMIC DISORDERS 276
7.9.2 ENDOCRINE DISORDERS 276
8 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE 278
8.1 INTRODUCTION 279
8.2 HOSPITALS 280
8.2.1 HOSPITALS TO HOLD LARGEST MARKET SHARE THROUGHOUT FORECAST PERIOD 280
8.3 AMBULATORY SURGERY CENTERS/CLINICS 282
8.3.1 INCREASING PREFERENCE FOR AMBULATORY CARE TO FUEL DEMAND FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES 282
8.4 HOME CARE SETTINGS 284
8.4.1 HOME CARE SETTINGS TO REGISTER HIGHEST GROWTH RATE 284
8.5 DIAGNOSTIC CENTERS 285
8.5.1 RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT MARKET GROWTH 285
8.6 OTHER FACILITIES OF USE 287
9 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION 289
9.1 INTRODUCTION 290
9.2 NORTH AMERICA 291
9.2.1 US 304
9.2.1.1 US to dominate North American pharmaceutical drug delivery market 304
9.2.2 CANADA 315
9.2.2.1 Government support for research and rising prevalence of chronic diseases to drive market 315
9.3 EUROPE 326
9.3.1 GERMANY 337
9.3.1.1 Growing focus of pharmaceutical companies on developing innovative drug delivery products to drive market 337
9.3.2 FRANCE 348
9.3.2.1 Presence of leading pharmaceutical companies and rising prevalence of chronic diseases to drive market 348
9.3.3 ITALY 359
9.3.3.1 Increasing focus on clinical research and growing popularity of branded drugs to drive demand 359
9.3.4 UK 370
9.3.4.1 Increasing incidence and prevalence of chronic and infectious diseases to drive market 370
9.3.5 SPAIN 381
9.3.5.1 Increase in biologics production to support market growth 381
9.3.6 REST OF EUROPE 391
9.4 ASIA PACIFIC 402
9.4.1 CHINA 415
9.4.1.1 High diabetes incidence and favorable government initiatives to drive market 415
9.4.2 JAPAN 426
9.4.2.1 Favorable government initiatives and increased geriatric population to drive market growth in Japan 426
9.4.3 INDIA 437
9.4.3.1 Growing generic demand and rising government initiatives to drive market 437
9.4.4 AUSTRALIA 448
9.4.4.1 Favorable government initiatives and outlook for pharma sector to support growth 448
9.4.5 SOUTH KOREA 459
9.4.5.1 Growing pharmaceutical segment to support demand for delivery technologies 459
9.4.6 REST OF ASIA PACIFIC 470
9.5 LATIN AMERICA 481
9.5.1 BRAZIL 493
9.5.1.1 Investments and government support to attract multinational pharma companies to Brazil 493
9.5.2 MEXICO 503
9.5.2.1 Growth and diversification in Mexico’s pharmaceutical exports to drive market 503
9.5.3 REST OF LATIN AMERICA 513
9.6 MIDDLE EAST & AFRICA 524
9.6.1 GCC COUNTRIES 536
9.6.1.1 Rising healthcare expenditure to drive market growth 536
9.6.2 REST OF MIDDLE EAST & AFRICA 546
10 COMPETITIVE LANDSCAPE 557
10.1 OVERVIEW 557
10.2 KEY PLAYER STRATEGY/RIGHT TO WIN 557
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN PHARMACEUTICAL DRUG DELIVERY MARKET 558
10.3 REVENUE ANALYSIS 559
10.4 MARKET SHARE ANALYSIS 559
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 561
10.5.1 STARS 561
10.5.2 EMERGING LEADERS 562
10.5.3 PERVASIVE PLAYERS 562
10.5.4 PARTICIPANTS 562
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 563
10.5.5.1 Company footprint 563
10.5.5.2 Route of administration footprint 564
10.5.5.3 Region footprint 565
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 566
10.6.1 PROGRESSIVE COMPANIES 566
10.6.2 RESPONSIVE COMPANIES 566
10.6.3 DYNAMIC COMPANIES 566
10.6.4 STARTING BLOCKS 566
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 568
10.7 VALUATION & FINANCIAL METRICS 569
10.7.1 FINANCIAL METRICS 569
10.7.2 COMPANY VALUATION 569
10.8 BRAND/PRODUCT COMPARISON 570
10.9 COMPETITIVE SCENARIO 571
10.9.1 PRODUCT LAUNCHES & APPROVALS 571
10.9.2 DEALS 572
10.9.3 EXPANSIONS 573
10.9.4 OTHER DEVELOPMENTS 573
11 COMPANY PROFILES 574
11.1 KEY PLAYERS 574
11.1.1 JOHNSON & JOHNSON SERVICES, INC. 574
11.1.1.1 Business overview 574
11.1.1.2 Products offered 575
11.1.1.3 Recent developments 583
11.1.1.3.1 Product approvals 583
11.1.1.3.2 Deals 584
11.1.1.3.3 Other developments 585
11.1.1.4 MnM view 586
11.1.1.4.1 Right to win 586
11.1.1.4.2 Strategic choices 586
11.1.1.4.3 Weaknesses and competitive threats 586
11.1.2 NOVARTIS AG 587
11.1.2.1 Business overview 587
11.1.2.2 Products offered 588
11.1.2.3 Recent developments 592
11.1.2.3.1 Product approvals 592
11.1.2.3.2 Deals 593
11.1.2.4 MnM view 593
11.1.2.4.1 Right to win 593
11.1.2.4.2 Strategic choices 593
11.1.2.4.3 Weaknesses and competitive threats 593
11.1.3 F. HOFFMANN-LA ROCHE LTD. 594
11.1.3.1 Business overview 594
11.1.3.2 Products offered 595
11.1.3.3 Recent developments 597
11.1.3.3.1 Product approvals 597
11.1.3.3.2 Deals 598
11.1.3.4 MnM view 599
11.1.3.4.1 Right to win 599
11.1.3.4.2 Strategic choices 599
11.1.3.4.3 Weaknesses and competitive threats 599
11.1.4 PFIZER INC. 600
11.1.4.1 Business overview 600
11.1.4.2 Products offered 602
11.1.4.3 Recent developments 611
11.1.4.3.1 Product approvals 611
11.1.4.3.2 DEALS 613
11.1.4.4 MnM view 613
11.1.4.4.1 Right to win 613
11.1.4.4.2 Strategic choices 614
11.1.4.4.3 Weaknesses and competitive threats 614
11.1.5 BECTON, DICKINSON AND COMPANY 615
11.1.5.1 Business overview 615
11.1.5.2 Products offered 617
11.1.5.3 Recent developments 620
11.1.5.3.1 Product launches 620
11.1.5.3.2 Other developments 620
11.1.5.4 MnM view 620
11.1.5.4.1 Right to win 620
11.1.5.4.2 Strategic choices 620
11.1.5.4.3 Weaknesses and competitive threats 621
11.1.6 GLAXOSMITHKLINE PLC 622
11.1.6.1 Business overview 622
11.1.6.2 Products offered 624
11.1.6.3 Recent developments 628
11.1.6.3.1 Product approvals 628
11.1.6.3.2 Deals 628
11.1.6.3.3 Other developments 628
 
11.1.7 MERCK & CO., INC. 629
11.1.7.1 Business overview 629
11.1.7.2 Products offered 631
11.1.7.3 Recent developments 636
11.1.7.3.1 Product approvals 636
11.1.7.3.2 Deals 637
11.1.8 SANOFI 638
11.1.8.1 Business overview 638
11.1.8.2 Products offered 640
11.1.8.3 Recent developments 643
11.1.8.3.1 Product approvals 643
11.1.8.3.2 Deals 644
11.1.9 BAYER AG 645
11.1.9.1 Business overview 645
11.1.9.2 Products offered 646
11.1.9.3 Recent developments 648
11.1.9.3.1 Product approvals 648
11.1.9.3.2 Deals 649
11.1.9.3.3 Expansions 650
11.1.10 AMGEN, INC. 651
11.1.10.1 Business overview 651
11.1.10.2 Products offered 652
11.1.10.3 Recent developments 653
11.1.10.3.1 Product approvals 653
11.1.10.3.2 Deals 654
11.1.11 ABBVIE INC. 655
11.1.11.1 Business overview 655
11.1.11.2 Products offered 656
11.1.11.3 Recent developments 659
11.1.11.3.1 Product launches & approvals 659
11.1.11.3.2 Deals 660
11.1.11.3.3 Expansions 660
11.1.12 GENMAB A/S 661
11.1.12.1 Business overview 661
11.1.12.2 Products offered 662
11.1.12.3 Recent developments 662
11.1.12.3.1 Product approvals 662
11.1.12.3.2 Deals 663
11.1.13 GILEAD SCIENCES, INC. 664
11.1.13.1 Business overview 664
11.1.13.2 Products offered 665
11.1.13.3 Recent developments 666
11.1.13.3.1 Product approvals 666
11.1.13.3.2 Deals 667
11.1.13.3.3 Other developments 668
11.1.14 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 669
11.1.14.1 Business overview 669
11.1.14.2 Products offered 671
11.1.14.3 Recent developments 672
11.1.14.3.1 Product approvals 672
11.1.14.3.2 Deals 673
11.1.15 ASTRAZENECA 674
11.1.15.1 Business overview 674
11.1.15.2 Products offered 676
11.1.15.3 Recent developments 678
11.1.15.3.1 Product approvals 678
11.1.15.3.2 Deals 681
11.1.16 ELI LILLY AND COMPANY 682
11.1.16.1 Business overview 682
11.1.16.2 Products offered 683
11.1.16.3 Recent developments 685
11.1.16.3.1 Product approvals 685
11.1.16.3.2 Deals 687
11.1.16.3.3 Expansions 687
11.1.17 TEVA PHARMACEUTICAL INDUSTRIES LTD. 688
11.1.17.1 Business overview 688
11.1.17.2 Products offered 689
11.1.17.3 Recent developments 690
11.1.17.3.1 Product approvals & launches 690
11.1.17.3.2 Deals 692
11.2 OTHER PLAYERS 693
11.2.1 NOVO NORDISK A/S 693
11.2.2 GLENMARK PHARMACEUTICALS LTD. 695
11.2.3 VIATRIS INC 699
11.2.4 BRISTOL-MYERS SQUIBB COMPANY 701
11.2.5 SANDOZ GROUP AG 702
11.2.6 GERRESHEIMER AG 705
11.2.7 BOSTON SCIENTIFIC CORPORATION 706
11.2.8 CMP PHARMA 707
11.2.9 RUSAN PHARMA 708
 
12 APPENDIX 709
12.1 DISCUSSION GUIDE 709
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 715
12.3 CUSTOMIZATION OPTIONS 717
12.4 RELATED REPORTS 717
12.5 AUTHOR DETAILS 718